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Background: Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and its derivative, everolimus, are
potent immunosuppressive and antiproliferative drugs. Inflammatory diseases are characterized by immunological
dysfunction, and monocyte recruitment underlies the mechanism of cell damage. Chemokines attract inflammatory
cells to sites of inflammation. Interleukin-8 (IL-8/CXCL8); the monocyte chemoattractant protein-1 (MCP-1/CCL2);
the regulated on activation, normal T cell expressed, presumably secreted protein (RANTES/CCL5); the macrophage
inflammatory protein (MIP)-1α (CCL3); and MIP-1β (CCL4) are involved in the pathogenesis of inflammation. However,
whether mTOR inhibitors moderate the production of chemokines in monocytes remains unclear.
Methods: A human monocyte cell line, THP-1, and primary monocytes obtained from human volunteers, were
stimulated using lipopolysaccharide (LPS), and then treated with sirolimus. The expression of the MCP-1, RANTES,
IL-8, MIP-1α, MIP-1β, and TNF-α proteins was measured using enzyme-linked immunosorbent assays, and intracellular
signalling was examined using western blotting.
Results: Sirolimus significantly suppressed the LPS-induced expression of MCP-1, IL-8, RANTES, MIP-1α, and MIP-1β in the
THP-1 cells and human primary monocytes. The mitogen-activated protein kinase (MAPK) inhibitors that were examined
suppressed the LPS-induced expression of MCP-1, IL-8, RANTES, MIP-1α, and MIP-1β. In addition, sirolimus suppressed
the LPS-induced phosphorylation of p38 and p65 in the THP-1 and human primary monocytes.
Conclusion: Sirolimus downregulates the expression of chemokines in monocytes, including MCP-1, RANTES, IL-8,
MIP-1α, and MIP-1β, by inhibiting the NF-κB-p65 and MAPK-p38 signalling pathways.
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Mammalian target of rapamycin (mTOR) is critical to cell
differentiation, migration, and survival [1]. Inhibitors of
mTOR, such as sirolimus or everolimus, have exhibited
antiinflammatory, antifibrotic, antitumor, and antifungal
properties, suggesting that mTOR signalling is involved in
various cellular functions [2]. Activation of mTOR phos-
phorylated p70 ribosomal S6kinase and eukaryotic initi-
ation factor-4E leads to cell hypertrophy, macrophage,* Correspondence: pedhung@gmail.com; shlin@kmu.edu.tw
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unless otherwise stated.T cell proliferation, and infiltration [1]. Recently, mTOR
inhibitors have been applied to anticancer therapy [3] to
prevent restenosis of the coronary arteries after angio-
plasty [4], and used in clinical trials and research pertain-
ing to the tuberous sclerosis complex [5] and Alzheimer’s
disease [6]. In kidney disease, although mTOR inhibitors
are limited by the risk of exacerbating preexisting protein-
uria [7], possibly attributable to inhibiting the vascular
endothelial growth factor [8], mTOR has ameliorated the
tubulointerstitial disease associated with chronic protein-
uria in experimental animal models and decreased pro-
teinuria values in patients with steroid-resistant nephrotic
syndrome [9,10].
Monocytes, which can differentiate into macrophages
and dendritic cells, contribute to the pathogenesis of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 In cell viability tests, treatment with sirolimus in
concentrations of 1, 5, and 10 ng/mL did not affect cell viability
in the THP-1 cells (a) and human monocytes (b).
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eases, by secreting cytokines and chemokines, recruiting
and activating leukocyte subsets that play various roles in
inflammation by interacting with chemokine receptors
[11]. Monocyte chemoattractant protein-1(MCP-1)/CCL2;
chemokine (C-X-C motif) ligand 3 (CXCL3); the regulated
on activation, normal T cell expressed, and presumably se-
creted protein (RANTES)/CCL5; macrophage inflamma-
tory protein (MIP-1α)/CCL3; MIP-1β/CCL4; interleukin-8
(IL-8)/CXCL8; TNF-α; and corresponding receptors are
involved in monocyte recruitment during inflammation
[12]. In clinical applications, serum or urinary levels of
these chemokines and expression in disease tissue could
serve as biomarkers of disease diagnosis, prognosis, or
treatment responses [13-16].
However, few studies have investigated the effect
mTOR inhibitors exert on the expression of these che-
mokines. We hypothesized that mTOR inhibitors mod-
ulated these chemokines in monocytes, and clarified
the detailed intracellular pathway mechanisms by which
modulation occur, including mitogen-activated protein
kinase (MAPK) and nuclear factor κB (NF-κB). We de-




A human monocyte cell line, THP-1 (American Type
Culture Collection, Rockville, MD, USA), was cultured
in an RPMI 1640 medium (Sigma-Aldrich, St. Louis,
MO, USA) supplemented with 10% foetal bovine serum,
100 U/mL of penicillin, and 100 μg/mL of streptomycin
at 37°C in 5% CO2 in a humidified incubator. The THP-
1 cells were collected by centrifugation, and resuspended
in a fresh RPMI medium. Twenty-four well plates were
seeded with 106 cells/mL and incubated for 24 h. In
preparation for the human primary monocyte experi-
ments, peripheral blood samples were collected from 3
healthy volunteers after we obtained informed consent.
The volunteers had no personal or family history of al-
lergies. This study was approved by the Institutional Re-
view Board of Kaohsiung Medical University Hospital
(KMUH-IRB-20130333).
The blood samples were diluted with an equal volume of
phosphate-buffered saline. Peripheral blood mononuclear
cells (PBMCs) were isolated using density-gradient centri-
fugation (Lymphoprep, Oslo, Norway). Primary monocytes
were isolated from the other PBMCs by using magnetically
activated cell sorting involving an anti-CD 14 monoclonal
antibody (Milteny Biotec, Bergisch Gladbach, Germany).
The cells were stimulated using 0.2 μg/mL of lipopolysac-
charide (LPS; Sigma-Aldrich) for 2 h before being treated
using 0, 1, 5, or 10 ng/mL of sirolimus (Sigma-Aldrich).
The cell supernatants were collected after 24 and 48 h.Cell viability assay
After LPS stimulation, the THP-1 cells were treated
using 1, 5, or 10 ng/mL of sirolimus for 24 h, and cell
viability was assessed using the WST-1 Cell Viability and
Proliferation Assay (Roche Diagnostics, Indianapolis, IN,
USA).Quantification of chemokine expression
The intracellular levels of MCP-1, IL-8, RANTES, MIP-
1α, MIP-1β, and TNF-α proteins in the cell supernatants
were determined using a commercially available enzyme-
linked immunosorbent assay (ELISA) kit (R&D System,
Minneapolis, MN, USA). The optical density of the ELISA
samples was measured at 450 and 540 nm using a Dyna-
tech MRX plate reader (Dynatech Laboratories, Chantilly,
VA, USA), and the ELISA data were analysed using Reve-
lation software (Westwood, NJ, USA).
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factor-kappa B assay
The THP-1 cells were treated for 1 h using 1 of 3
MAPK inhibitors: PD 98059, SB203580, or SP600125
(Sigma-Aldrich); the NF-κB inhibitor, BAY 11–7085;
or the vehicle control. The cells were stimulated using 0.2
μg/mL of LPS for 48 h, and then the cell supernatants
were collected for ELISA analysis.
Western blot analysis
The THP-1 cells were stimulated using 0.2 μg/mL of
LPS for 1 h and treated with 0, 5, or 10 ng/mL of siroli-
mus for 2 h. The cells were lysed using an equal volume
of ice-cold lysis, and centrifuged at 13 000 × g for 15
min. The total amount of protein in the cell-lysate su-
pernatants was determined using the BCA Protein Assay
Reagent (Thermo-Fisher, Waltham, MA, USA). Cell-lysate
samples were prepared using equivalent total proteinFigure 2 Sirolimus suppressed LPS-induced MCP-1, RANTES, and IL-8
monocytes (b), (d), and (f) after 24 h of LPS stimulation (**P < .01 a
treatment).concentrations, and analysed by employing western
blotting. The blots were probed using primary antibodies
(Santa Cruz Biotechnology, Dallas, TX, USA) generated
against the following proteins: p38, signal regulated kinase
(ERK), c-Jun N-terminal kinase (JNK), phosphorylated
(phospho)-p38, phospho-ERK, phospho-JNK, NF-κB (p65),
and phospho-p65. Primary antibody reactivity was visua-
lised using a horseradish peroxidase-conjugated secondary
antibody and an enhanced chemiluminescence system (GE
Healthcare Life Sciences, Waukesha, WI, USA).
Statistical analyses
Each experiment was replicated 6 times, and the data
were presented as the mean ± standard deviation. Differ-
ences between the experimental and control groups were
analysed using the Mann–Whitney U-test, and P < .05
was considered to indicate a statistically significant inter-
group difference.production in THP-1 cells (a), (c), and (e), and primary human
nd ***P < .005 between groups of LPS only and LPS plus sirolimus
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Sirolimus did not reduce the viability of the THP-1 cells
The 24-h sirolimus treatment did not significantly change
the viability of the THP-1 cells and primary monocytes,
compared with the control group (Figure 1 and b).
Sirolimus suppressed lipopolysaccharide-induced chemokine
expression in THP-1 cells and human primary monocytes
Sirolimus (1–10 ng/mL) significantly reduced the LPS-
induced expression of MCP-1, RANTES, and IL-8 in the
THP-1 cells (Figure 2a,c and e) and human primary mono-
cytes (Figure 2b,d and f). In addition, Sirolimus (5 ng/mL)
significantly reduced the LPS-induced expression of MIP-1α
in the THP-1 cells (Figure 3a and c), whereas the expression
of both MIP-1α and MIP-1β was reduced in LPS-treated
human primary monocytes (Figure 3b and d). The data sug-
gested that mTOR inhibition suppressed the expression of
nephrotic-syndrome-related chemokines in the THP-1 cells
and human primary monocytes. Sirolimus (1–10 ng/mL)
did not significantly reduce the LPS-induced expres-
sion of TNF-i in THP-1 cells and human primary
monocytes (Figure 4a and b).Figure 3 Sirolimus suppressed LPS-induced MIP-1α, and MIP-1β prod
(b) and (d) after 24 h of LPS stimulation (**P < .01 and ***P < .005 betSirolimus suppressed lipopolysaccharide-induced
monocyte chemoattractant protein-1 expression
through mitogen-activated protein kinase and nuclear
factor-κB pathways in THP-1 cells
Figure 5a and e indicate that SB203580 (p38-MAPK in-
hibitor), SP600125 (JNK-MAPK inhibitor), and PD98059
(ERK-MAPK inhibitor) suppressed the LPS-induced ex-
pression of MCP-1 and IL-8, suggesting that MAPK sig-
nalling is involved in the LPS-induced expression of
MCP-1 and IL-8 in THP-1 cells. Figure 5b, d, and f show
that the NF-κB inhibitor, BAY 11–7085, significantly re-
duced the LPS-induced expression of MCP-1, RANTES,
and IL-8 in THP-1 cells, signifying that NF-κB inhibitor
signalling is involved in the LPS-induced expression of
MCP-1, RANTES, and IL-8 in THP-1 cells.
As shown in Figure 6a and c, SP600125 and PD98059
reduced the LPS-induced expression of MIP-1α and
MIP-1β in THP-1 cells; SB203580 suppressed the LPS-
induced expression of MIP-1β, but did not reduce the
expression of MIP-1α in THP-1 cells. Figure 6b and d
show that BAY 11–7085 reduced the LPS-induced ex-
pression of MIP-1α and MIP-1β in THP-1 cells. Thus,uction in THP-1 cells (a) and (c), and primary human monocytes
ween groups of LPS only and LPS plus sirolimus treatment).
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Figure 4 Sirolimus did not suppress LPS-induced TNF-α production
in THP-1 cells (a) and primary human monocytes (b).
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fecting the LPS-induced expression of MIP-1α and MIP-
1β in THP-1 cells.
In addition, sirolimus reduced the LPS-induced phos-
phorylation of p38 and p65 in human primary mono-
cytes, but did not significantly affect the phosphorylation
of JNK or ERK. This phenomenon indicates that siroli-
mus suppresses the expression of nephrotic-syndrome-
related chemokines by modulating p38- and p65-mediated
signalling pathways (Figure 7).
Discussion
In this study, we demonstrated that the mTOR inhibitor
suppressed chemokines, including MCP-1, RANTES, IL-8,
and MIP- 1β in THP-1 cells, and MCP-1, RANTES, IL-8,
MIP-1α, and MIP-1β in human primary monocytes. In
addition, we determined that the suppressive effects of sir-
olimus in monocytes were mediated by the MAPK-p38
and NF-κB-p65 signalling pathways.
The immune system plays a crucial role in disease
pathogenesis, evaluation, and treatment. With the signal-
ling of chemokines and their corresponding receptors,
monocytes gather in the target organ following injuryand differentiate into macrophages and dendritic cells
[12]. The inflammatory chemokine MCP-1 is a member
of the cysteine-cysteine (CC) chemokine family [17]. In
CCL2 (−/−) mice, neoplasms that grew failed to accu-
mulate dendritic cell-like APCs in response to chemo-
therapy [18]. MCP-1 is also critical to the pathogenesis
of atherosclerosis; considerable evidence has verified that
the monocyte-containing MCPs and macrophage influ-
ence the growth of other cell types within the athero-
sclerotic lesion [19]. An increased level of MCP-1
expression in renal tissues is essential to monocyte/
macrophage infiltration during the pathogenesis of renal
injury [20]. In clinical applications, serum or urinary levels
of MCP-1 could be markers of disease progression and
treatment response [21,22]. The RANTES protein is also a
member of the CC chemokine family. Previous studies
have shown that increased expression of the RANTES
protein 3 to 5 d after the activation of T cells facilitated
leukocyte infiltration and increased the duration of the in-
flammatory response [23]. The RANTES and its receptor
have been detected in various hematological malignancies
and lymphomas and in many solid tumors. Inhibiting the
binding of RANTES to its receptor or the secretion of
RANTES is a new chemotherapy strategy [24]. A previous
study suggested that the expression of RANTES in the
cerebral microcirculation of patients with Alzheimer’s dis-
ease is elevated, and that oxidative stress upregulated
RANTES expression in rat brain endothelial cells [25].
Another study determined that the expression of the
MCP-1 and RANTES proteins by tubular epithelial cells
correlated with proteinuria and was associated with renal
interstitial cell infiltration and fibrosis [26]. Manipulating
the expression of RANTES might facilitate a beneficial
treatment strategy for various diseases, including cancer,
dementia, and renal diseases [27]. The plasma level of IL-8
was significantly higher during nephrotic-syndrome relapse
than during remission [28]. IL-8 and IL-17 enhance the ac-
tivity of matrix metalloproteinase-2 and −9 (MMP-2,-9)
which in turn increase the metastatic activity of the under-
lying malignancy [29]. IL-8 and other chemokines have
been considered to play a role in developing peripheral
artery disease [30]. Macrophage inflammatory markers
(MIP-1α, β) have been determined to be critical factors
affecting atherosclerosis [31,32]. A previous study sug-
gested that MIP-1α and β were expressed by infiltrat-
ing leukocytes, the renal tubular cells, and peritubular
capillaries in patients with kidney diseases [33].
mTOR is a component of two major intracellular sig-
nalling complexes (mTORC1 and mTORC2) that play
dissimilar roles downstream. mTORC1 is activated by
growth factors and amino acids and controls cellular
proliferation, promoting processes such as DNA trans-
lation, RNA transcription, ribosomal biogenesis, and
cell cycle progression [34]. Rapamycin is an alternative
Figure 5 PD98059 suppressed LPS-induced MCP-1 (a), RANTES (c), and IL-8 (e) expression. SB203580 and SP600125 could only suppress
LPS-induced MCP-1 and IL-8 expression. BAY 11–7085 suppressed LPS-induced MCP-1 (b), RANTES (d), and IL-8 (f) expression.
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hibitors used to treat chronic allograft damage [35].
Currently, mTOR inhibitors have been applied to treat
several types of illnesses, including cancer, arterioscler-
osis, and autoimmune diseases; however, numerous proin-
flammatory side effects have been observed, including
interstitial pneumonitis, glomerulonephritis with pro-
teinuria, lymphocytic alveolitis, and anemia [36-39].
Weichhart et al. determined that the mTOR inhibitor
upregulated IL-12 production in innate immune cells,
such as monocyte/macrophages, through the transcription
factor NF-kB, but blocked the release of interleukin-10
through the transcription factor STAT3 [40]. mTOR in-
hibitors could also induce macrophage apoptosis in M2
phase rather than in M1 phase [41]. These results were
contributed to understanding inflammatory conditions of
mTOR inhibitors, and facilitated new therapeutic options.The role of mTOR inhibitors in the secretion of chemo-
kines by mononuclear cells requires further evaluation.
In this study, we determined the suppressive effect
mTOR inhibitors exert on chemokines secreted in cell
models and human primary monocytes. The results indi-
cated that mTOR inhibitors may facilitate therapeutic
clinical treatments. In addition, we investigated the intra-
cellular signal pathway to explore the detailed mechanism
by which suppression occurred. The NF-κB-, ERK-, and
p38-mediated activation of MAPK signal transduction
pathways is critical to the inflammatory response [42,43].
The suppressive effect sirolimus exerts on the expression
of LPS-induced phosphorylation of p38 and p65, but not
of JNK or ERK, suggested that the mTOR inhibitor sup-
pressed the expression of chemokines by modulating the
p38- and p65-mediated signalling pathways. The immuno-
suppressive effect of glucocorticoids occurred because of
Figure 6 SP600125 and PD98059 suppressed LPS-induced MIP-1α (a) and MIP-1β (c) expression. BAY 11–7085 suppressed both LPS-induced
MCP-1α and MCP-1β expression (b, d). These results suggested that the p38, JNK-MAPKs, and NF-кB pathways were critical to LPS-induced MDC
expression by monocytes.
Lin et al. BMC Immunology 2014, 15:37 Page 7 of 9
http://www.biomedcentral.com/1471-2172/15/37the MAPKs [44]. The calcineurin inhibitors cyclospor-
ine and tacrolimus reduce the responses of NF-κB acti-
vation and therapeutically regulate the expression of
MAPKs [45], and mycophenolate mofetil inhibits the
phosphorylation of NF-κB and JNK, and is a possibleFigure 7 Sirolimus suppressed LPS-induced pp65 and pp38 expressioalternative treatment [46]. Our results suggested that
mTOR inhibitors suppress the expression of chemo-
kines by inhibiting the NF-κB-p65 and MAPK-p38 signal-
ling pathways in monocytes. Further pathway investigation
may be necessary.n in THP-1 cells (a, b, c, d).
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Certain limitations to our findings must be considered.
We evaluated the suppressive effects sirolimus exerted
on the expression of monocyte-secreted chemokines in
cell models. In future studies, primary monocytes can be
collected from patients with diseases to investigate the
effect of mTOR inhibitors and verify our findings.
Conclusions
An mTOR inhibitor, sirolimus, downregulated the expres-
sion of chemokines, including MCP-1, IL-8, RANTES,
MIP-1α, and MIP-1β, by inhibiting the NF-κB-p65 and
MAPK-p38 signalling pathways in monocytes. These re-
sults indicated that mTOR inhibitors can be used in treat-
ments for inflammatory diseases. Future studies including
larger patient numbers are necessary.
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